688185.SH
康希诺
SSE · Healthcare · Biotechnology · CN
CNY 75.50
−2.35%Aug 27, 2026, 10:22 UTC
CanSino Biologics reported its first-half 2026 results, with revenue of 550 million yuan, up 43.81% year-on-year, and a net loss attributable to shareholders of 720,800 yuan, compared with a loss of 13.4854 million yuan in the same period of 2025.
Aug 26, 2026, 10:21 UTC
CanSino Biologics announced it is advancing research and development of mRNA vaccines for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as InVivoCAR-related therapies, all currently in early stages.
Source:Aug 20, 2026, 13:15 UTC
CanSino Biologics entered into an exclusive commercialization cooperation agreement with Yuanda Life Sciences for its tetanus vaccine.
Source:Aug 20, 2026, 10:23 UTC
CanSino Biologics received a drug registration certificate from China's National Medical Products Administration for its adsorbed tetanus vaccine, which is used for non-neonatal tetanus prevention.
Aug 20, 2026, 06:42 UTC
CanSino Biologics' stock surged over 50% in half-day trading, driven by Moderna's positive Phase 3 trial results for its mRNA cancer vaccine.
Source:Aug 20, 2026, 01:46 UTC
On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.
Source:Aug 12, 2026, 08:43 UTC
CanSino Biologics announced that the first batch of its new three-component acellular pertussis, diphtheria, and tetanus combined vaccine for infants, Pankangxin, received the Biological Products Batch Issuance Certificate, marking the official start of market supply.
Source: